WeedMD Inc (CVE:WMD) (OTCQX:WDDMF) announced Tuesday that its products and strains have been included in University Health Networks’ (UNH) Medical Cannabis Real-World Evidence study.
UNH is launching nationwide clinical trials studying the effects of cannabis use on chronic plain, sleep issues, anxiety and depression.
Participating patients can select their medical cannabis products using the online portal created by Medical Cannabis by Shoppers Drug Mart. WeedMD is one of the first licensed producers (LPs) to have its products and strains included, the company said.
READ: WeedMD works key amendments into existing credit facility
“Recognizing the importance of strain validation as cannabis products advance through Canada’s medical and pharmaceutical channels is paramount for building trust and accountability in our industry, and we congratulate UHN, Shoppers and TruTrace on this breakthrough initiative,” WeedMD CEO Angelo Tsebelis said in a statement.
WeedMD is also the only LP to have all its cannabis strains registered under TruTrace Technologies Inc's (CSE:TTT) (OTC:BKKSF) proprietary StrainSecure cannabis tracing and verification platform.
“As the only producer with all its products registered under StrainSecure, we are proud to be included,” Tsebelis said. “Patients and their medical practitioners expect traceability, origin assurance and consistency in their medicine, particularly when used as a natural alternate for treating traumatic indications such as pain management — this study will present much needed evidence and we’re looking forward to the results.”
The study is being led by Hance Clarke, director of pain services at Toronto General Hospital.
“Shoppers Drug Mart is trusted by patients and healthcare providers to provide medical products that have been tested and validated, regardless of whether that medication came from a lab or a greenhouse,” Shoppers VP of Business Development/Cannabis Strategy Ken Weisbrod said. “Many partners came together to launch this initiative and we are proud to work with industry leaders to further our ability to provide Canadians with safe, consistent, rigorously tested cannabis-based medication.”
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel